Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arete Therapeutics, which develops soluble epoxide hydrolase inhibitors, has appointed James Sabry as its new president and CEO.
Subscribe to our email newsletter
Dr Sabry has been a strategic advisor and member of the board of directors since March 2008. Dr Sabry succeeds Dinesh Patel in the position of president and CEO, who will remain as a consultant to the company.
Dr Sabry is chairman of the board of directors and former CEO of Cytokinetics, a company he co-founded in August 1997. Dr Sabry has received an MD from Queen’s University and a PhD in cell biology from the University of California, San Francisco.
James Topper, chairman of the board of Arete, said: “We are confident that his exceptional entrepreneurial leadership will guide the company in the years to come as Arete continues to advance its pipeline of innovative compounds through clinical development.”